Publications

Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018

Fu M, Naci H, Booth CM, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner AK

Childhood Cancer Drugs in China: An Overview and Comparison of Regulatory Approvals in China and the United States.

Int J Cancer
Zhang Y, Wagner AK, Du H, Han T, Gupta S, Denburg AE, Frazier AL, Guan X, Shi L

Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs.

JAMA Intern Med
Naci H, Guan X, Woloshin S, Xu Z, Wagner AK

Forecasting essential childhood cancer drug need: An innovative model-based approach.

Cancer
Hughes TM, Empringham B, Wagner AK, Ward ZJ, Yeh J, Gupta S, Frazier AL, Denburg AE

Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending.

Cancer Commun (Lond)
Huang T, Wagner AK, Bai L, Huang C, Guan X, Shi L

Efficacy and costs of spinal muscular atrophy drugs

Sci Transl Med
Darrow JJ, Sharma M, Shroff M, Wagner AK

Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States.

JCO Oncol Pract
Ferrario A, Xu X, Zhang F, Ross-Degnan D, Wharam JF, Wagner AK

What are the volume and budget needs to provide chemotherapy to all children with acute lymphoblastic leukaemia in Thailand? Development and application of an estimation tool

BMJ Open
Sruamsiri R, Ferrario A, Ross-Degnan D, Denburg AE, Frazier AL, Gupta S, Ward ZJ, Yeh JM, Wagner AK

The Complex Cancer Care Coverage Environment - What is the Role of Legislation? A Case Study from Massachusetts.

J Law Med Ethics
Leopold C, Haffajee RL, Lu CY, Wagner AK

Article 3: 1-year impact of supervision, performance assessment, and recognition strategy (SPARS) on prescribing and dispensing quality in Ugandan health facilities.

J Pharm Policy Pract
Trap B, Sembatya MN, Imi M, Seru M, Wagner AK, Ross-Degnan D

Sales of anti-cancer medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand

Bull World Health Organ
Ferrario A, Stephens P, Guan X, Ross-Degnan D, Wagner A

Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand.

BMC Health Serv Res
Leopold C, Lu CY, Wagner AK

Differences in reimbursement listing of anticancer therapies in China: an observational study.

BMJ Open
Guan X, Zhang Y, Wushouer H, Shi L, Ross-Degnan D, Wagner AK

Medication Use During Pregnancy in Mainland China: A Cross-Sectional Analysis of a National Health Insurance Database

Clinical Epidemiology
Zhang J, Ung COL, Wagner AK, Guan X, Shi L

Costs and effectiveness of the supervision, performance assessment and recognition (SPARS) strategy for medicines management in Uganda.

J Pharm Policy Pract
Kwesiga B, Wagner AK, Seru M, Ross-Degnan D, Trap B

Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study.

BMJ Open
Guan X, Wushouer H, Yang M, Han S, Shi L, Ross-Degnan D, Wagner AK

The Brazilian private pharmaceutical market after the first ten years of the generics law.

J Pharm Policy Pract
Bertoldi AD, Wagner AK, Emmerick ICM, Chaves LA, Stephens P, Ross-Degnan D

Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program.

Pharmacoecon Open
Leopold C, Araujo-Lane C, Rosenberg C, Gilkey M, Wagner AK

A new analytic tool developed to assess safe use recommendations.

Pharmacoepidemiol Drug Saf
Cocoros NM, Wagner A, Haynes K, Petrone AB, Fazio-Eynullayeva E, Ding Y, Izem R, Lee JY, Major JM, Nguyen M, Ju J

Pharmaceutical system strengthening in Uganda: implementing a holistic, evidence-informed, long-term strategy.

J Pharm Policy Pract
Oteba M, Wagner AK, Seru M, Embrey M, Trap B